Depression symptoms increase the risk for initiation or switching to biologic therapy in pediatric inflammatory bowel disease patients in remission
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Depression symptoms increase the risk for initiation or switching to biologic therapy in pediatric inflammatory bowel disease patients in remission ; volume:23 ; number:1 ; day:13 ; month:10 ; year:2023 ; pages:1-5 ; date:12.2023
BMC gastroenterology ; 23, Heft 1 (13.10.2023), 1-5, 12.2023
- Creator
-
Milo, F.
Angelino, G.
Romeo, E.F
De Angelis, P.
Tabarini, P.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12876-023-02993-z
- URN
-
urn:nbn:de:101:1-2024020112231575968429
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Milo, F.
- Angelino, G.
- Romeo, E.F
- De Angelis, P.
- Tabarini, P.
- SpringerLink (Online service)
Other Objects (12)
Socioeconomic equality in initiation of biologic treatment in Danish patients with inflammatory bowel disease
Biologic treatment of Japanese patients with inflammatory bowel disease
Impact of Online Prescription Management Systems on Biologic Treatment Initiation
Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis
Long-term remission and biologic persistence rates: 12-year real-world data
Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease
Serum biomarkers confirming stable remission in inflammatory bowel disease
Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration
A Retrospective Observational Study of Patterns of Biologic Drug Change in Inflammatory Bowel Disease
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Biologic basis of pigmentation
Low dose Naltrexone for induction of remission in inflammatory bowel disease patients
Socioeconomic equality in initiation of biologic treatment in Danish patients with inflammatory bowel disease
Biologic treatment of Japanese patients with inflammatory bowel disease
Impact of Online Prescription Management Systems on Biologic Treatment Initiation
Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis
Long-term remission and biologic persistence rates: 12-year real-world data
Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease
Serum biomarkers confirming stable remission in inflammatory bowel disease
Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration
A Retrospective Observational Study of Patterns of Biologic Drug Change in Inflammatory Bowel Disease
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Biologic basis of pigmentation
Low dose Naltrexone for induction of remission in inflammatory bowel disease patients
Socioeconomic equality in initiation of biologic treatment in Danish patients with inflammatory bowel disease
Biologic treatment of Japanese patients with inflammatory bowel disease
Impact of Online Prescription Management Systems on Biologic Treatment Initiation
Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis
Long-term remission and biologic persistence rates: 12-year real-world data
Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease
Serum biomarkers confirming stable remission in inflammatory bowel disease
Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration
A Retrospective Observational Study of Patterns of Biologic Drug Change in Inflammatory Bowel Disease
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Biologic basis of pigmentation